Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
SGLT2 Inhibitors in Acute Heart Failure
Author(s): Hugo Prado-Prado , Sergio Raposeiras-Roubín Added: 2 months ago

Heart Failure
Factor XIa Inhibitors’ Future Position in AF
Author(s): Maki Komiyama , Moritake Iguchi , Hiromichi Wada , et al Added: 1 year ago

Anticoagulation
Oral P2Y12 Inhibitors and Drug Interactions
Author(s): Elisabetta Bigagli , Jacopo Angelini , Alessandro Mugelli , et al Added: 11 months ago

Anticoagulation

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Alberto Alen Andrés , María Salgado , Maria Fernández García , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 6 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Kidney Metabolic
Enlicitide: Oral PCSK9 Inhibitor Lowers LDL-C by 56%
Added: 2 months ago Source:  Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an… View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
Author(s): Byoung Geol Choi , Seung-Woon Rha , Se Yeon Choi , et al Added: 1 year ago

Anticoagulation
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19
Author(s): Andrea Di Lenarda , Nicola Ferri , Massimiliano Lanzafame , et al Added: 1 year ago

COVID-19

CV Disease in Special Populations
Lp(a) and Atherosclerosis
Author(s): Annalisa Filtz , Leandro Slipczuk , Martha Gulati Added: 2 months ago

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Raúl Ludeña , Raúl Ptaszynski Lanza , Beatriz Nieves Ureña , et al Added: 1 month ago

Prevention & Chronic Conditions